Lv41
510 积分 2024-04-02 加入
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis
6小时前
已完结
Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States
6小时前
待确认
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
1个月前
已完结
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?
1个月前
已完结
SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation
3个月前
已完结
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial
3个月前
已完结
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
3个月前
已完结
Liver-specific thyroid hormone receptor-β agonism alleviates alcoholic steatohepatitis (ASH) in mice
7个月前
已完结
Phase 3 drug pipelines in the treatment of non‐alcoholic steatohepatitis
1年前
已完结
Current state of radiomic research in pancreatic cancer: focusing on study design and reproducibility of findings
皖公网安备34019202002308
